Role of chemokine CCL2 and its receptor CCR2 in neurodegenerative diseases

详细信息    查看全文

• 作者：Shambhunath Bose (1)
  Jungsook Cho (1)
  
• 关键词：Neurodegenerative diseases ; CCL2 ; CCR2 ; G protein ; coupled receptor
• 刊名：Archives of Pharmacal Research
• 出版年：2013
• 出版时间：September 2013
• 年：2013
• 卷：36
• 期：9
• 页码：1039-1050
• 全文大小：507KB
• 参考文献：1. Andjelkovic, A.V., L. Song, K.A. Dzenko, H. Cong, and J.S. Pachter. 2002. Functional expression of CCR2 by human fetal astrocytes. / The Journal of Neuroscience Research 70: 219-31. CrossRef
  2. Arakelyan, A., J. Petrkova, Z. Hermanova, A. Boyajyan, J. Lukl, and M. Petrek. 2005. Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction. / Mediators of Inflammation 3: 175-79. CrossRef
  3. Bacon, K., M. Baggiolini, H. Broxmeyer, R. Horuk, I. Lindley, A. Mantovani, K. Maysushima, P. Murphy, H. Nomiyama, J. Oppenheim, A. Rot, T. Schall, M. Tsang, R. Thorpe, J. Van Damme, M. Wadhwa, O. Yoshie, A. Zlotnik, and K. Zoon. 2002. Chemokine/chemokine receptor nomenclature. / The Journal of Interferon and Cytokine Research 22: 1067-068. CrossRef
  4. Bajetto, A., R. Bonavia, S. Barbero, T. Florio, and G. Schettini. 2001. Chemokines and their receptors in the central nervous system. / Frontiers in Neuroendocrinology 22: 147-84. CrossRef
  5. Banisadr, G., R.D. Gosselin, P. Mechighel, P. Kitabgi, W. Rostène, and S.M. Parsadaniantz. 2005a. Highly regionalized neuronal expression of monocyte chemoattractant protein-1 (MCP-1/CCL2) in rat brain: evidence for its colocalization with neurotransmitters and neuropeptides. / The Journal of Comparative Neurology 489: 275-92. CrossRef
  6. Banisadr, G., R.D. Gosselin, P. Mechighel, W. Rostène, P. Kitabgi, and S. Mélik Parsadaniantz. 2005b. Constitutive neuronal expression of CCR2 chemokine receptor and its colocalization with neurotransmitters in normal rat brain: functional effect of MCP-1/CCL2 on calcium mobilization in primary cultured neurons. / The Journal of Comparative Neurology 492: 178-92. CrossRef
  7. Beall, C.J., S. Mahajan, D.E. Kuhn, and P.E. Kolattukudy. 1996. Site-directed mutagenesis of monocyte chemoattractant protein-1 identifies two regions of the polypeptide essential for biological activity. / Biochemical Journal 313: 633-40.
  8. Boddeke, E.W., I. Meigel, S. Frentzel, N.G. Gourmala, J.K. Harrison, M. Buttini, O. Spleiss, and P. Gebicke-H?rter. 1999. Cultured rat microglia express functional beta-chemokine receptors. / The Journal of Neuroimmunology 98: 176-84. CrossRef
  9. Bonecchi, R., E. Galliera, E.M. Borroni, M.M. Corsi, M. Locati, and A. Mantovani. 2009. Chemokines and chemokine receptors: an overview. / Frontiers in Bioscience 14: 540-51. CrossRef
  10. Brosnan, C.F., and C.S. Raine. 1996. Mechanisms of immune injury in multiple sclerosis. / Brain Pathology 6: 243-57. CrossRef
  11. Charo, I.F., S.J. Myers, A. Herman, C. Franci, A.J. Connolly, and S.R. Coughlin. 1994. Molecular cloning and functional expression of two monocyte chemoattractant protein 1 receptors reveals alternative splicing of the carboxyl-terminal tails. / Proceedings of the National Academy of Sciences of the United States of America 91: 2752-756. CrossRef
  12. Che, X., W. Ye, L. Panga, D.C. Wu, and G.Y. Yang. 2001. Monocyte chemoattractant protein-1 expressed in neurons and astrocytes during focal ischemia in mice. / Brain Research 902: 171-77. CrossRef
  13. Chen, Y., J.M. Hallenbeck, C. Ruetzler, D. Bol, K. Thomas, N.E. Berman, and S.N. Vogel. 2003. Overexpression of monocyte chemoattractant protein 1 in the brain exacerbates ischemic brain injury and is associated with recruitment of inflammatory cells. / The Journal of Cerebral Blood Flow and Metabolism 23: 748-55. CrossRef
  14. Cho, J., and D.L. Gruol. 2008. The chemokine CCL2 activates p38 mitogen-activated protein kinase pathway in cultured rat hippocampal cells. / The Journal of Neuroimmunology 199: 94-03. CrossRef
  15. Conductier, G., N. Blondeau, A. Guyon, J.L. Nahon, and C. Rovère. 2010. The role of monocyte chemoattractant protein MCP1/CCL2 in neuroinflammatory diseases. / The Journal of Neuroimmunology 224: 93-00. CrossRef
  16. Dawson, J., W. Miltz, A.K. Mir, and C. Wiessner. 2003. Targeting monocyte chemoattractant protein-1 signalling in disease. / Expert Opinion on Therapeutic Targets 7: 35-8. CrossRef
  17. Deshmane, S.L., S. Kremlev, S. Amini, and B.E. Sawaya. 2009. Monocyte chemoattractant protein-1 (MCP-1): an overview. / The Journal of Interferon and Cytokine Research 29: 313-26. CrossRef
  18. Dimitrijevic, O.B., S.M. Stamatovic, R.F. Keep, and A.V. Andjelkovic. 2007. Absence of the chemokine receptor CCR2 protects against cerebral ischemia/reperfusion injury in mice. / Stroke 38: 1345-353. CrossRef
  19. Dirnagl, U., C. Iadecola, and M.A. Moskowitz. 1999. Pathobiology of ischaemic stroke: an integrated view. / Trends in Neurosciences 22: 391-97. CrossRef
  20. Ebisawa, M., T. Yamada, C. Bickel, D. Klunk, and R.P. Schleimer. 1994. Eosinophil transendothelial migration induced by cytokines. III. Effect of the chemokine RANTES. / The Journal of Immunology 153: 2153-160.
  21. Esiri, M.M. 2007. The interplay between inflammation and neurodegeneration in CNS disease. / The Journal of Neuroimmunology 184: 4-6. CrossRef
  22. Fuentes, M.E., S.K. Durham, M.R. Swerdel, A.C. Lewin, D.S. Barton, J.R. Megill, R. Bravo, and S.A. Lira. 1995. Controlled recruitment of monocytes and macrophages to specific organs through transgenic expression of monocyte chemoattractant protein-1. / The Journal of Immunology 155: 5769-776.
  23. Galimberti, D., C. Fenoglio, C. Lovati, E. Venturelli, I. Guidi, B. Corrà, D. Scalabrini, F. Clerici, C. Mariani, N. Bresolin, and E. Scarpini. 2006. Serum MCP-1 levels are increased in mild cognitive impairment and mild Alzheimer’s disease. / Neurobiology of Aging 27: 1763-768. CrossRef
  24. Gao, Y.J., and R.R. Ji. 2010. Chemokines, neuronal-glial interactions, and central processing of neuropathic pain. / Pharmacology and Therapeutics 126: 56-8. CrossRef
  25. Gerard, C., and B.J. Rollins. 2001. Chemokines and disease. / Nature Immunology 2: 108-15. CrossRef
  26. Glabinski, A.R., V. Balasingam, M. Tani, S.L. Kunkel, R.M. Strieter, V.W. Yong, and R.M. Ransohoff. 1996. Chemokine monocyte chemoattractant protein-1 is expressed by astrocytes after mechanical injury to the brain. / The Journal of Immunology 156: 4363-368.
  27. Goncharova, L.B., and A.O. Tarakanov. 2008. Why chemokines are cytokines while their receptors are not cytokine ones? / Current Medicinal Chemistry 15: 1297-304. CrossRef
  28. Gong, J.H., L.G. Ratkay, J.D. Waterfield, and I. Clark-Lewis. 1997. An antagonist of monocyte chemoattractant protein 1 (MCP-1) inhibits arthritis in the MRL-lpr mouse model. / The Journal of Experimental Medicine 186: 131-37. CrossRef
  29. Gosselin, R.D., C. Varela, G. Banisadr, P. Mechighel, W. Rostene, P. Kitabgi, and S. Melik-Parsadaniantz. 2005. Constitutive expression of CCR2 chemokine receptor and inhibition by MCP-1/CCL2 of GABA-induced currents in spinal cord neurones. / The Journal of Neurochemistry 95: 1023-034. CrossRef
  30. Gourmala, N.G., M. Buttini, S. Limonta, A. Sauter, and H.W. Boddeke. 1997. Differential and time-dependent expression of monocyte chemoattractant protein-1 mRNA by astrocytes and macrophages in rat brain: effects of ischemia and peripheral lipopolysaccharide administration. / The Journal of Neuroimmunology 74: 35-4. CrossRef
  31. Gouwy, M., S. Struyf, J. Catusse, P. Proost, and J. Van Damme. 2004. Synergy between proinflammatory ligands of G protein-coupled receptors in neutrophil activation and migration. / The Journal of Leukocyte Biology 76: 185-94. CrossRef
  32. Horuk, R. 2001. Chemokine receptors. / Cytokine and Growth Factor Reviews 12: 313-35. CrossRef
  33. Horuk, R. 2009. Chemokine receptor antagonists: overcoming developmental hurdles. / Nature reviews Drug discovery 8: 23-3. CrossRef
  34. Huang, D., M. Tani, J. Wang, Y. Han, T.T. He, J. Weaver, I.F. Charo, V.K. Tuohy, B.J. Rollins, and R.M. Ransohoff. 2002. Pertussis toxin-induced reversible encephalopathy dependent on monocyte chemoattractant protein-1 overexpression in mice. / The Journal of Neuroscience 22: 10633-0642.
  35. Huang, D., J. Wujek, G. Kidd, T.T. He, A. Cardona, M.E. Sasse, E.J. Stein, J. Kish, M. Tani, I.F. Charo, A.E. Proudfoot, B.J. Rollins, T. Handel, and R.M. Ransohoff. 2005. Chronic expression of monocyte chemoattractant protein-1 in the central nervous system causes delayed encephalopathy and impaired microglial function in mice. / The FASEB Journal 19: 761-72. CrossRef
  36. Hughes, P.M., P.R. Allegrini, M. Rudin, V.H. Perry, A.K. Mir, and C. Wiessner. 2002. Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model. / The Journal of Cerebral Blood Flow and Metabolism 22: 308-17. CrossRef
  37. Hulkower, K., C.F. Brosnan, D.A. Aquino, W. Cammer, S. Kulshrestha, M.P. Guida, D.A. Rapoport, and J.W. Berman. 1993. Expression of CSF-1, c-fms, and MCP-1 in the central nervous system of rats with experimental allergic encephalomyelitis. / The Journal of Immunology 150: 2525-533.
  38. Ishizuka, K., T. Kimura, R. Igata-yi, S. Katsuragi, J. Takamatsu, and T. Miyakawa. 1997. Identification of monocyte chemoattractant protein-1 in senile plaques and reactive microglia of Alzheimer’s disease. / Psychiatry and Clinical Neurosciences 51: 135-38. CrossRef
  39. Izikson, L., R.S. Klein, I.F. Charo, H.L. Weiner, and A.D. Luster. 2000. Resistance to experimental autoimmune encephalomyelitis in mice lacking the CC chemokine receptor (CCR)2. / The Journal of Experimental Medicine 192: 1075-080. CrossRef
  40. Karpus, W.J., and R.M. Ransohoff. 1998. Chemokine regulation of experimental autoimmune encephalomyelitis: temporal and spatial expression patterns govern disease pathogenesis. / The Journal of Immunology 161: 2667-671.
  41. Kim, J.S., S.C. Gautam, M. Chopp, C. Zaloga, M.L. Jones, P.A. Ward, and K.M. Welch. 1995. Expression of monocyte chemoattractant protein-1 and macrophage inflammatory protein-1 after focal cerebral ischemia in the rat. / The Journal of Neuroimmunology 56: 127-34. CrossRef
  42. Kiyota, T., M. Yamamoto, H. Xiong, M.P. Lambert, W.L. Klein, H.E. Gendelman, R.M. Ransohoff, and T. Ikezu. 2009. CCL2 accelerates microglia-mediated Aβ oligomer formation and progression of neurocognitive dysfunction. / PLoS ONE 4: e6197. CrossRef
  43. Kothandan, G., C.G. Gadhe, and S.J. Cho. 2012. Structural insights from binding poses of CCR2 and CCR5 with clinically important antagonists: a combined in silico study. / PLoS ONE 7: e32864. CrossRef
  44. Kuang, Y., Y. Wu, H. Jiang, and D. Wu. 1996. Selective G protein coupling by C–C chemokine receptors. / The Journal of Biological Chemistry 271: 3975-978. CrossRef
  45. Kumai, Y., H. Ooboshi, J. Takada, M. Kamouchi, T. Kitazono, K. Egashira, S. Ibayashi, and M. Iida. 2004. Anti-monocyte chemoattractant protein-1 gene therapy protects against focal brain ischemia in hypertensive rats. / The Journal of Cerebral Blood Flow and Metabolism 24: 1359-368. CrossRef
  46. Lau, E.K., C.D. Paavola, Z. Johnson, J.P. Gaudry, E. Geretti, F. Borlat, A.J. Kungl, A.E. Proudfoot, and T.M. Handel. 2004. Identification of the glycosaminoglycan binding site of the CC chemokine, MCP-1: implications for structure and function in vivo. / The Journal of Biological Chemistry 279: 22294-2305. CrossRef
  47. Lee, Y.J., S.B. Han, S.Y. Nam, K.W. Oh, and J.T. Hong. 2010. Inflammation and Alzheimer’s disease. / Archives of Pharmacal Research 33: 1539-556. CrossRef
  48. Locati, M., G. Lamorte, W. Luini, M. Introna, S. Bernasconi, A. Mantovani, and S. Sozzani. 1996. Inhibition of monocyte chemotaxis to C–C chemokines by antisense oligonucleotide for cytosolic phospholipase A2. / The Journal of Biological Chemistry 271: 6010-016. CrossRef
  49. Losy, J., and J. Zaremba. 2001. Monocyte chemoattractant protein-1 is increased in the cerebrospinal fluid of patients with ischemic stroke. / Stroke 32: 2695-696. CrossRef
  50. Lucchinetti, C.F., W. Brück, M. Rodriguez, and H. Lassmann. 1996. Distinct patterns of multiple sclerosis pathology indicates heterogeneity on pathogenesis. / Brain Pathology 6: 259-74. CrossRef
  51. Mahad, D.J., and R.M. Ransohoff. 2003. The role of MCP-1 (CCL2) and CCR2 in multiple sclerosis and experimental autoimmune encephalomyelitis (EAE). / Seminars in Immunology 15: 23-2. CrossRef
  52. McManus, C., J.W. Berman, F.M. Brett, H. Staunton, M. Farrell, and C.F. Brosnan. 1998. MCP-1, MCP-2 and MCP-3 expression in multiple sclerosis lesions: an immunohistochemical and in situ hybridization study. / The Journal of Neuroimmunology 86: 20-9. CrossRef
  53. Mirabelli-Badenier, M., V. Braunersreuther, G.L. Viviani, F. Dallegri, A. Quercioli, E. Veneselli, F. Mach, and F. Montecucco. 2011. CC and CXC chemokines are pivotal mediators of cerebral injury in ischaemic stroke. / Thrombosis and Haemostasis 105: 409-20. CrossRef
  54. Monteclaro, F.S., and I.F. Charo. 1996. The amino-terminal extracellular domain of the MCP-1 receptor, but not the RANTES/MIP-1alpha receptor, confers chemokine selectivity. Evidence for a two-step mechanism for MCP-1 receptor activation. / The Journal of Biological Chemistry 271: 19084-9092. CrossRef
  55. Monteclaro, F.S., and I.F. Charo. 1997. The amino-terminal domain of CCR2 is both necessary and sufficient for high affinity binding of monocyte chemoattractant protein 1. Receptor activation by a pseudo-tethered ligand. / The Journal of Biological Chemistry 272: 23186-3190. CrossRef
  56. Moreaux, J. 2010. CCR2 (chemokine (C–C motif) receptor 2). / Atlas of Genetics and Cytogenetics in Oncology and Haematology 14: 938-41.
  57. Old, E.A., and M. Malcangio. 2012. Chemokine mediated neuron-glia communication and aberrant signalling in neuropathic pain states. / Current Opinion in Pharmacology 12: 67-3. CrossRef
  58. Proudfoot, A.E., C.A. Power, and M.K. Schwarz. 2010. Anti-chemokine small molecule drugs: a promising future? / Expert Opinion on Investigational Drugs 19: 345-55. CrossRef
  59. Ransohoff, R.M., T.A. Hamilton, M. Tani, M.H. Stoler, H.E. Shick, J.A. Major, M.L. Estes, D.M. Thomas, and V.K. Tuohy. 1993. Astrocyte expression of mRNA encoding cytokines IP-10 and JE/MCP-1 in experimental autoimmune encephalomyelitis. / The FASEB Journal 7: 592-00.
  60. Ransohoff, R.M. 2002. The chemokine system in neuroinflammation: an update. / The Journal of Infectious Diseases 186(Suppl 2): S152–S156. CrossRef
  61. Rollins, B.J. 1991. JE/MCP-1: an early-response gene encodes a monocyte-specific cytokine. / Cancer Cells 3: 517-24.
  62. Rollins, B.J. 1996. Monocyte chemoattractant protein 1: a potential regulator of monocyte recruitment in inflammatory disease. / Molecular Medicine Today 2: 198-04. CrossRef
  63. Rollins, B.J. 1997. Chemokines. / Blood 90: 909-28.
  64. Rostène, W., P. Kitabgi, and S.M. Parsadaniantz. 2007. Chemokines: a new class of neuromodulator? / Nature Reviews Neuroscience 8: 895-03. CrossRef
  65. Semple, B.D., T. Kossmann, and M.C. Morganti-Kossmann. 2010. Role of chemokines in CNS health and pathology: a focus on the CCL2/CCR2 and CXCL8/CXCR2 networks. / The Journal of Cerebral Blood Flow and Metabolism 30: 459-73. CrossRef
  66. Simpson, J.E., J. Newcombe, M.L. Cuzner, and M.N. Woodroofe. 1998. Expression of monocyte chemoattractant protein-1 and other beta-chemokines by resident glia and inflammatory cells in multiple sclerosis lesions. / The Journal of Neuroimmunology 84: 238-49. CrossRef
  67. Simpson, J., P. Rezaie, J. Newcombe, M.L. Cuzner, D. Male, and M.N. Woodroofe. 2000. Expression of the beta-chemokine receptors CCR2, CCR3 and CCR5 in multiple sclerosis central nervous system tissue. / The Journal of Neuroimmunology 108: 192-00. CrossRef
  68. Sozzani, S., D. Zhou, M. Locati, M. Rieppi, P. Proost, M. Magazin, N. Vita, J. van Damme, and A. Mantovani. 1994. Receptors and transduction pathways for monocyte chemotactic protein-2 and monocyte chemotactic protein-3. Similarities and differences with MCP-1. / The Journal of Immunology 152: 3615-622.
  69. Terashima, Y., N. Onai, M. Murai, M. Enomoto, V. Poonpiriya, T. Hamada, K. Motomura, M. Suwa, T. Ezaki, T. Haga, S. Kanegasaki, and K. Matsushima. 2005. Pivotal function for cytoplasmic protein FROUNT in CCR2-mediated monocyte chemotaxis. / Nature Immunology 6: 827-35. CrossRef
  70. Thathiah, A., and B. De Strooper. 2011. The role of G protein-coupled receptors in the pathology of Alzheimer’s disease. / Nature Reviews Neuroscience 12: 73-7. CrossRef
  71. Tran, E.H., K. Hoekstra, N. van Rooijen, C.D. Dijkstra, and T. Owens. 1998. Immune invasion of the central nervous system parenchyma and experimental allergic encephalomyelitis, but not leukocyte extravasation from blood, are prevented in macrophage-depleted mice. / The Journal of Immunology 161: 3767-775.
  72. Van Coillie, E., J. Van Damme, and G. Opdenakker. 1999. The MCP/eotaxin subfamily of CC chemokines. / Cytokine and Growth Factor Reviews 10: 61-6. CrossRef
  73. Wain, J.H., J.A. Kirby, and S. Ali. 2002. Leucocyte chemotaxis: examination of mitogen-activated protein kinase and phosphoinositide 3-kinase activation by monocyte chemoattractant proteins-1, -2, -3 and -4. / Clinical and Experimental Immunology 127: 436-44. CrossRef
  74. Wang, X., and G.Z. Feuerstein. 1995. Induced expression of adhesion molecules following focal brain ischemia. / The Journal of Neurotrauma 12: 825-32. CrossRef
  75. Xia, M., and Z. Sui. 2009. Recent developments in CCR2 antagonists. / Expert Opinion on Therapeutic Patents 19: 295-03. CrossRef
  76. Yamamoto, M., M. Horiba, J.L. Buescher, D. Huang, H.E. Gendelman, R.M. Ransohoff, and T. Ikezu. 2005. Overexpression of monocyte chemotactic protein-1/CCL2 in beta-amyloid precursor protein transgenic mice show accelerated diffuse beta-amyloid deposition. / American Journal of Pathology 166: 1475-485. CrossRef
  77. Yamasaki, R., L. Liu, J. Lin, and R.M. Ransohoff. 2012. Role of CCR2 in immunobiology and neurobiology. / Clinical and Experimental Neuroimmunology 3: 16-9. CrossRef
  78. Youssef, S., G. Wildbaum, G. Maor, N. Lanir, A. Gour-Lavie, N. Grabie, and N. Karin. 1998. Long-lasting protective immunity to experimental autoimmune encephalomyelitis following vaccination with naked DNA encoding C–C chemokines. / The Journal of Immunology 161: 3870-879.
  79. Zhang, Y., and B.J. Rollins. 1995. A dominant negative inhibitor indicates that monocyte chemoattractant protein 1 functions as a dimer. / Molecular and Cellular Biology 15: 4851-855.
  
• 作者单位：Shambhunath Bose (1)
  Jungsook Cho (1)
  
  1. College of Pharmacy, Dongguk University, Goyang, 410-820, Republic of Korea
  
• ISSN：1976-3786

文摘

Chemokines are members of the chemoattractant cytokine family. They play key roles in the trafficking of leukocytes and in the induction of chemotaxis through the activation of G protein-coupled receptor. Considerable interest has been paid to these molecules to elucidate their roles in the unique inflammatory responses elicited in the central nervous system (CNS). Chemokine CCL2 (also known as monocyte chemoattractant protein-1, MCP-1) is one of the vital chemokines that control the migration and infiltration of monocytes/macrophages. CCL2 and its receptor CCR2 have been shown to be induced and involved in various neurodegenerative disorders including Alzheimer’s disease, multiple sclerosis, and ischemic brain injury. The present review will focus on the biological and pathophysiological aspects of CCL2 and CCR2 in the CNS and the possible therapeutic approaches for targeting these two proteins to combat neurodegenerative diseases.